The announcement comes days ahead of an FDA advisory panel meeting to discuss concerns about the drugs. Last month a federal report concluded epilepsy drugs are associated with a higher risk of suicidal tendencies.
An FDA spokesman says the agency is proposing the strong black box warning based on that analysis but will still seek the panel's input.
